Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Martin Wermke et al. published in Nature Medicine:

“In contrast to CAR T cells, TCR-engineered T cells can target intracellular tumor-associated antigens – critical in tackling solid tumors.

A phase 1 trial of IMA203, a PRAME-directed TCR-T therapy, shows promising activity in HLA-A*02+ patients with PRAME+ refractory solid tumors (like melanoma and sarcoma).

41 patients treated
52.5% overall response rate
28.9% confirmed responses
Low rates of severe CRS (4.9%)
Rapid engraftment, long-term persistence
Stronger responses linked to higher PRAME expression and T cell infiltration

Bottom line: IMA203 is safe, durable, and shows encouraging anti-tumor activity across multiple solid tumor types. More to come!

ClinicalTrials.gov: NCT03686124.”

“Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial”

Authors: Martin Wermke, Dejka Araurjo, Manik Chatterjee, Apostolia Tsimberidou, Tobias Holderried, Harpreet Singh-Jasuja, Steffen Walter, Toni Weinschenk, Jason Luke, Cedrik Britten et al.

$Yan Leyfman: A phase 1 trial of IMA203 shows promising activity in HLA-A*02+ patients with PRAME+ refractory solid tumors$